Distress in a Pandemic - The Association of the Coronavirus Disease-2019 (COVID-19) Pandemic with Distress and Quality of Life in Hematopoietic Stem Cell Transplantation (HSCT)

The global coronavirus disease-2019 (COVID-19) pandemic has drastically disrupted many aspects of life and healthcare in unparalleled ways. For patients with cancer, it has impacted both treatment and recovery trajectories.1, 2 Patients with hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT) are especially vulnerable to care changes imposed by the pandemic due to factors associated with HSCT, including the intensive treatment with a prolonged hospitalization, high burden of physical symptoms due to potential toxic side effects, and quality of life (QOL) challenges in recovery.

Source: Biology of Blood and Marrow Transplantation - September 15, 2021 Category: Hematology Authors: Hermioni L. Amonoo, Carlisle EW Topping, Madison A. Clay, Matthew J. Reynolds, Julia Rice, Lauren E. Harnedy, Regina M. Longley, Thomas W. LeBlanc, Joseph A. Greer, Yi-Bin Chen, Zachariah DeFilipp, Stephanie J. Lee, Jennifer S. Temel, Areej El-Jawahri Source Type: research